![Jason Werner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jason Werner
Direttore operativo presso ALIMERA SCIENCES, INC.
Patrimonio netto: 686 250 $ in data 31/05/2024
Posizioni attive di Jason Werner
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALIMERA SCIENCES, INC. | Direttore operativo | 02/10/2023 | - |
Direttore/Membro del Consiglio | 17/05/2023 | 02/10/2023 | |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jason Werner
Precedenti posizioni note di Jason Werner
Società | Posizione | Inizio | Fine |
---|---|---|---|
SightStream Biotherapeutics
![]() SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Amministratore Delegato | 01/05/2021 | 30/09/2023 |
Eyevance Pharmaceuticals LLC
![]() Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Direttore operativo | 01/09/2017 | 01/09/2020 |
Fondatore | 01/09/2017 | 01/09/2020 | |
Eyevance Pharmaceuticals Holdings, Inc.
![]() Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Direttore operativo | 01/09/2017 | 01/09/2020 |
Formazione di Jason Werner
University of New Hampshire | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Chief Operating Officer | 3 |
Director/Board Member | 2 |
Founder | 1 |
Settori
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ALIMERA SCIENCES, INC. | Health Technology |
Aziende private | 4 |
---|---|
Eyevance Pharmaceuticals LLC
![]() Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | Health Technology |
Eyevance Pharmaceuticals Holdings, Inc.
![]() Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | Health Technology |
InflammX Therapeutics, Inc.
![]() InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
SightStream Biotherapeutics
![]() SightStream Biotherapeutics BiotechnologyHealth Technology SightStream Biotherapeutics develops cytoprotectives to reverse ocular cell death. The company is based in Dallas-Fort Worth, TX. The company was founded by Jack Jiagang Zhao. | Health Technology |
- Borsa valori
- Insiders
- Jason Werner
- Esperienza